News & Views
Telix is pleased to announce the launch of PSMA PET/CT Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in prostate cancer…
Read more
Telix announces that the FDA has granted Orphan Drug Designation for TLX66 (90Y-besilesomab), for conditioning treatment prior to hematopoietic stem cell transplant…
Read more
Telix announces agreement with Xiel for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® in the UK and Republic of…
Read more
Telix announces significant progress in advancing the Company’s glioblastoma therapy candidate TLX101 into the next stage of clinical…
Read more
News,
Telix provides a material update on the development of its radiopharmaceutical production facility in Brussels South (Seneffe) in the Wallonia region of…
Read more
Telix welcomes the updated 2022 ‘Guidelines on Prostate Cancer’ (the Guidelines) from the European Association of Urology (EAU), which demonstrate an increasing recognition of the clinical utility of prostate specific membrane antigen…
Read more
Telix announces the ZIRCON Phase III study of investigational kidney cancer imaging agent, TLX250-CDx has dosed the target enrolment of 252…
Read moreTelix Pharmaceuticals Limited Releases Full-Year 2021 Results and 2021 Annual…
Read more
Telix announces a commercial distribution agreement with Global Medical Solutions Australia (GMSA), for Illuccix® in the Australian…
Read more
Telix announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for…
Read more